Can I read Treatment Of Joint Pain In Crohn’s Patients With Budesonide Controlled Ileal Release^§^ on EtoBox?

Treatment Of Joint Pain In Crohn’s Patients With Budesonide Controlled Ileal Release^§^ by Timothy Hj Florin; Hans Graffner; Lars‐Göran Nilsson; Tore Persson is a Medicine article available to read on EtoBox.

What is Treatment Of Joint Pain In Crohn’s Patients With Budesonide Controlled Ileal Release^§^ about?

## SUMMARY 1. Joint pain is a frequent manifestation of Crohn’s disease. Budesonide controlled ileal release (CIR) is a predominantly topically acting glucocorticosteroid, which is effective in treating active ileal or ileocaecal Crohn’s disease. 2. Therefore, it was of interest to study the effect of this predominantly topically acting therapy on the treatment of an extra‐intestinal symptom of Crohn’s disease by analysing data collected from budesonide CIR (Entocort^®^; Astra Draco AB, Lund, Sweden) trials. 3. Three large studies of budesonide CIR treatment in active Crohn’s disease provided a reliable source of clinical data. Of the 611 patients treated in the prospective double‐blind controlled trials, 291 had joint pain (arthritis/arthralgia) at entry, which was recorded as part of the Crohn’s Disease Activity Index. Statistical analysis was based on all patients treated, provided that the patient had joint pain at the start of treatment. 4. Daily oral budesonide CIR (9 mg) resulted in clinical remission of joint pain in 74% (95% confidence intervals (CI) 67–82%) of patients. This outcome was nearly twice as good as placebo (41%; 95% CI 34–57%) and as good as the outcome effect

Who reads Treatment Of Joint Pain In Crohn’s Patients With Budesonide Controlled Ileal Release^§^?

Author

Timothy Hj Florin; Hans Graffner; Lars‐Göran Nilsson; Tore Persson

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 0305-1870)

Published

2000

Language

EN

Field

Medicine (Health Sciences)